Chinese patient demand for intravenous therapy: a preliminary survey
Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached...
Saved in:
Published in | The Lancet (British edition) Vol. 386; p. S61 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
London
Elsevier Ltd
01.10.2015
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion.
We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study.
About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes.
Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings.
Jiangsu University and OHSU Foundation Global Health Center Fund. |
---|---|
AbstractList | Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion.
We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study.
About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes.
Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings.
Jiangsu University and OHSU Foundation Global Health Center Fund. Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1-5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund. Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0.74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1-5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund. Abstract Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics intravenously, and students faced with stressful exams receive amino acids intravenously. Adverse outcomes from intravenous infusion reached 0·74% in one study. In December 2011, China reported its citizens consumed on average 138 g antibiotics annually, ten-times the per capita use in the USA. 70% of inpatients in Chinese hospitals receive antibiotics compared with a maximum of 30% recommended by WHO. Overall, three times as many Chinese patients are prescribed penicillin compared with the international norm. Explanations for high rates of intravenous infusion usage range from market-based reforms rewarding physicians, hospitals, and manufacturers, to overwhelming patient demand. The aim of this study was to assess patient demand for intravenous infusion. Methods We collected qualitative information from participants in one health centre and one university: respectively, the Qilidian Community Health Service Center, Runzhou, Zhenjiang and Jiangsu University, Zhenjiang, Jiangsu Province, both of which reviewed and approved the project. We utilised the method of purposive sampling (a method used in the study of cultural phenomena) by selecting persons with knowledge or experience with intravenous infusion. Patients, health providers, and medical students served as respondents, each of whom provided informed verbal consent before discussing their views and experience with intravenous infusion (primary outcomes). People who were acutely sick and those unable to communicate in Mandarin or Cantonese were excluded. We observed the practice of and interviewed 30 patients (inpatients and outpatients), five nurses (including three head nurses), three pharmacists, 11 medical doctors and directors, and more than ten medical students. These participants were considered to form a representative group of stakeholders from which to obtain information for use in the design of a future formal research study. Findings About 30% of outpatients received intravenous infusions, which is substantially lower than rates of up to 96% reported in Guangdong Province. Patients receiving drugs intravenously typically presented with illnesses of varying severity: childhood pneumonia, weakness, diarrhoea, a few days' history of coughing or fever, tonsillitis, and dizziness secondary to low blood pressure. Intravenous treatment spanned 2 h/day for 1–5 days depending on the drug. Despite this time commitment, patient preference for intravenous treatment was dominated by the desire for rapid recovery driven by the need to return to school (to maintain academic competitiveness) or work (to maintain an income stream). These considerations surmounted patient perceptions of procedural risk, although needle puncture, unpleasant sensations, nausea, fainting, bruising, rash, and even antibiotic resistance, were acknowledged on occasion. The cost of intravenous drug delivery was considered acceptable. Doctors described huge patient loads, insufficient time to discuss the benefits and risks of intravenous infusion, and potential physician endangerment for failing to comply with a patient's wishes. Interpretation Although overuse of intravenous therapy might cause adverse outcomes, including the potential for antibiotic resistance, patient perception of rapid therapeutic benefit still dominates demand. The public has been urged by health departments to use intravenous infusion as a last resort, and not the norm, yet this risky practice continues. These preliminary observations provide the foundation to design a formal research-education study of stakeholder understanding of the use, value, and risks of intravenous infusion in primary healthcare settings. Funding Jiangsu University and OHSU Foundation Global Health Center Fund. |
Author | Kan, Jenny Zhu, Xinxing Lu, Rongzhu Wang, Tieying Spencer, Peter S |
Author_xml | – sequence: 1 givenname: Jenny surname: Kan fullname: Kan, Jenny organization: Oregon Health & Science University (OHSU), Portland, OR, USA – sequence: 2 givenname: Xinxing surname: Zhu fullname: Zhu, Xinxing organization: Qilidian Community Health Service Center, Runzhou, Zhenjiang, Jiangsu Province, China – sequence: 3 givenname: Tieying surname: Wang fullname: Wang, Tieying organization: Jiangsu University, Zhenjiang, Jiangsu, China – sequence: 4 givenname: Rongzhu surname: Lu fullname: Lu, Rongzhu email: lurz@mail.ujs.edu.cn organization: Jiangsu University, Zhenjiang, Jiangsu, China – sequence: 5 givenname: Peter S surname: Spencer fullname: Spencer, Peter S email: spencer@ohsu.edu organization: Jiangsu University, Zhenjiang, Jiangsu, China |
BookMark | eNqNkEuLFDEUhYOMYM_oTxAK3IyL0nvzqEorKtI-YcCFCr0LmeQWk7E6VSbVDf3vTXWLQoOMq7s55-Pc75ydxSESY48RniFg8_wroIS6aUVzieopQCN5vb7HFihbWSvZrs_Y4k_kATvP-RYAZANqwd6tbkKkTNVop0BxqjxtbPRVN6QqxCnZHcVhm6vphpId9y8qW42J-rAJ0aZ9lbdpR_uH7H5n-0yPft8L9v3D-2-rT_XVl4-fV2-vaie4XNYaHVzrrtNSWwlWkvMer1sHXqEQHq3tvGo1b1XH0WnheUNWKOHapW4AUVywyyN3TMPPLeXJbEJ21Pc2UhlpsJWN1krIZYk-OYneDtsUy7qS4povNQIvqZfHlEtDzok648JURAzz56E3CGY2bA6GzazPoDIHw2Zd2uqkPaawKVru7L059qi42gVKJrvi3pEPidxk_BDuJLw-Ibg-xOBs_4P2lP--ajI3cITMDFQHwgx49W_Afwz4BXNAvM8 |
CODEN | LANCAO |
CitedBy_id | crossref_primary_10_2196_12577 crossref_primary_10_1016_j_jhazmat_2024_133787 crossref_primary_10_3390_ijerph20043430 crossref_primary_10_1007_s11096_019_00898_0 crossref_primary_10_1016_j_scitotenv_2018_01_271 crossref_primary_10_3389_fpubh_2021_678785 crossref_primary_10_1007_s11356_017_0745_0 crossref_primary_10_1016_j_chemosphere_2023_138211 crossref_primary_10_1186_s41256_019_0097_z |
ContentType | Journal Article |
Copyright | 2015 Elsevier Ltd Elsevier Ltd Copyright Elsevier Limited Oct 1, 2015 |
Copyright_xml | – notice: 2015 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright Elsevier Limited Oct 1, 2015 |
DBID | AAYXX CITATION 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7U1 |
DOI | 10.1016/S0140-6736(15)00642-X |
DatabaseName | CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial Risk Abstracts |
DatabaseTitle | CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) Risk Abstracts |
DatabaseTitleList | ProQuest One Psychology Risk Abstracts |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1474-547X |
EndPage | S61 |
ExternalDocumentID | 3851788631 10_1016_S0140_6736_15_00642_X S014067361500642X 1_s2_0_S014067361500642X |
GeographicLocations | China, People's Rep., Guangdong Prov China, People's Rep., Jiangsu Prov USA China, People's Rep., Jiangsu |
GeographicLocations_xml | – name: China, People's Rep., Jiangsu Prov – name: China, People's Rep., Jiangsu – name: USA – name: China, People's Rep., Guangdong Prov |
GroupedDBID | --- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AAEDT AAEDW AAEJM AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ABWVN ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACRPL ACUHS ACVFH ADBBV ADCNI ADMUD ADNMO ADXHL ADZCM AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AGQPQ AHHHB AHMBA AHQJS AIGII AIIUN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKVCP AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EFKBS EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO Q~Q R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UKHRP UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 3V. 88A AACTN AAYOK ABTAH ACRZS AFCTW AFKWA AJOXV ALIPV AMFUW M0L PKN RIG SDF ABLVK ABYKQ AHPSJ AJBFU NHB XFK Y6R ZA5 AAYXX AGRNS CITATION 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7U1 |
ID | FETCH-LOGICAL-c3249-81c0b8ff848a40a4ecdd1b7c0d5133d1aafd578275f21c83d26ea353c79860113 |
IEDL.DBID | 7X7 |
ISSN | 0140-6736 |
IngestDate | Fri Jul 11 00:15:03 EDT 2025 Sat Aug 23 13:24:04 EDT 2025 Tue Jul 01 03:16:34 EDT 2025 Thu Apr 24 23:00:39 EDT 2025 Fri Feb 23 02:30:16 EST 2024 Sun Feb 23 10:19:31 EST 2025 Tue Aug 26 16:32:01 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3249-81c0b8ff848a40a4ecdd1b7c0d5133d1aafd578275f21c83d26ea353c79860113 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PQID | 1728298102 |
PQPubID | 40246 |
ParticipantIDs | proquest_miscellaneous_1746885349 proquest_journals_1728298102 crossref_citationtrail_10_1016_S0140_6736_15_00642_X crossref_primary_10_1016_S0140_6736_15_00642_X elsevier_sciencedirect_doi_10_1016_S0140_6736_15_00642_X elsevier_clinicalkeyesjournals_1_s2_0_S014067361500642X elsevier_clinicalkey_doi_10_1016_S0140_6736_15_00642_X |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20151001 |
PublicationDateYYYYMMDD | 2015-10-01 |
PublicationDate_xml | – month: 10 year: 2015 text: 20151001 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | The Lancet (British edition) |
PublicationYear | 2015 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
SSID | ssj0004605 |
Score | 2.160478 |
Snippet | Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given antibiotics... Abstract Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are... Background Treatment of medically trivial disorders by intravenous drug infusion has been widespread in China. Children with common colds are routinely given... |
SourceID | proquest crossref elsevier |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | S61 |
SubjectTerms | Amino acids Antibiotic resistance Antibiotics Blood pressure Global health Health services Hospitals Internal Medicine Medical personnel |
Title | Chinese patient demand for intravenous therapy: a preliminary survey |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S014067361500642X https://www.clinicalkey.es/playcontent/1-s2.0-S014067361500642X https://dx.doi.org/10.1016/S0140-6736(15)00642-X https://www.proquest.com/docview/1728298102 https://www.proquest.com/docview/1746885349 |
Volume | 386 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NS-QwFA-7I8heRFfF0dkhC3vQQ7Vp0zb1IqurDAvKsir0FtJ8gKB1nKow_73vtWkFGde99ND2l8LLy3u_Ju-DkB_AGJRLrQ5S5XjAy1JhDUgTWBWGLnLg8hUmOJ9fpJNr_rtICr_hVvuwys4mNoba3GvcIz_APkpRLsAfHk0fAuwahaervoXGZ7KEpctQq7MiW5QX2YS4v2bwHFz2N3dZsoeOOQqK93zTGyvduJ6zVbLiOSP92U7yGvlkq69k-dyfiq-TX9gE29aW-iKp1Ng7VRkKfJTe4Obtc1OIlba5VvNDquh0Zm-bfl6zOa2fZs92vkGuz06vTiaB744QaCBBuHenw1I4J7hQPFTcamNYmenQYMsWw5RyBmvVZ4mLmBaxiVKr4iTWWS7gL4zFm2RQ3Vd2i1AXA0-MRFpqZjhwABAzz00W5zqGIXg8JLyTi9S-dDh2sLiVC2LEWCIbccpiSPZ72LStnfERIO2ELrvEUDBlEqz7R8BsEdDWfkHWksk6kmGLRjDwYIQCUvRIzzlaLvE_Hx11eiFfv9Or6ZB87x_DksVzGFVZmG14h6cCaBLPt_89xA75AvwsaWMHR2TwOHuy34ADPZbjRtHhKk7YmCwdn178-fsCoS3_3w |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXVF5ioQUjgQSH0PiRxEGqKtRSbWm3F1ppb8axHQmppMumLdo_xW9kJq9KaKFcek3y2dJ4PPPFngfAa2QMtkyDi1JbqkgVhaUakD4KNo5LUaLLt5TgPDlKxyfq8zSZrsCvPheGwip7m9gYan_m6Ix8k_ooiVyjP9ye_YioaxTdrvYtNFq1OAiLn_jLVm_t7-L6vhFi79PxzjjqugpEDskDnXm5uNBlqZW2KrYqOO95kbnYU6sTz60tPdV4z5JScKelF2mwMpEuyzX-vXCJ496C20ri1qTM9B2-LA-zCam_yhja_DI8fMuTd0QERDT9my_8wys0rm5vDe53HJV9bJXqAayE6iHcmXS38I9gl5puhzqwrigr8-G7rTxD_su-0WHxZVP4lbW5XYsPzLLZPJw2_cPmC1ZfzC_D4jGc3IjcnsBqdVaFp8BKibxU6LRw3CvkHLisKveZzJ3EIZQcgerlYlxXqpw6ZpyaJTFpPDGNOM10BO8H2Kyt1XEdIO2FbvpEVDSdBr3JdcBsGTDUnQGoDTe1MHGLJjDyboIiUg_IjuO03OV_Jl3v9cJczTNsixG8Gl6jiaB7H1sFXG38RqUaaZnKn_17iJdwd3w8OTSH-0cHz-EecsOkjVtch9Xz-UXYQP51XrxolJ7B15veZb8BL-A5Yg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UCsUXqTdcrTqCgj7EzUwmyUQQka5La20RtLBv42QuUKjpdtNW9q_56zwnt4Ks1pe-JvlmYOZcvsycC8ALZAwmZN5GmQkykmVpqAaki7yJ4yACunxDCc77B9nOofw0S2dr8KvPhaGwyt4mNobanVg6Ix9THyVRKPSH49CFRXyZTN_PTyPqIEU3rX07jVZE9vzyJ_6-1e92J7jXL4WYfvy2vRN1HQYii0SCzr9sXKoQlFRGxkZ66xwvcxs7anviuDHBUb33PA2CW5U4kXmTpInNC4V_MjzBcW_AzTzJFemY2uarcjKb8PrL7KHx1-HhK56-JlIgotnf_OIfHqJxe9NNuN3xVfahFbA7sOaru7Cx393I34MJNeD2tWddgVbm_A9TOYZcmB3RwfFFUwSWtXley7fMsPnCHze9xBZLVp8vLvzyPhxey7o9gPXqpPIPgYUEOapQWWm5k8g_cItl4fKksAkOIZMRyH5dtO3KllP3jGO9Ij6Np7pZTj0bwZsBNm_rdlwFyPpF131SKppRjZ7lKmC-CujrzhjUmuta6LhFExg5OEERqQZkx3daHvM_k271cqEv5xlUZATPh9doLugOyFQedxu_kZlCiiaLR_8e4hlsoH7pz7sHe4_hFtLEtA1h3IL1s8W5f4JU7Kx82sg8g-_XrWS_ATW0PZg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chinese+patient+demand+for+intravenous+therapy%3A+a+preliminary+survey&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Kan%2C+Jenny%2C+BS&rft.au=Zhu%2C+Xinxing%2C+MD&rft.au=Wang%2C+Tieying%2C+MD&rft.au=Lu%2C+Rongzhu&rft.date=2015-10-01&rft.issn=0140-6736&rft.volume=386&rft.spage=S61&rft.epage=S61&rft_id=info:doi/10.1016%2FS0140-6736%2815%2900642-X&rft.externalDBID=ECK1-s2.0-S014067361500642X&rft.externalDocID=1_s2_0_S014067361500642X |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673615X00110%2Fcov150h.gif |